GPCRStructure Therapeutics Inc.
$25.51+8.2% 1Y
$25.51
$24.0152 weeks$93.79
GPCR as reported
- Net income
- −$215M
Net income · +20% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$225M
Free cash flow · +37% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.01
EPS · −3.8% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$215M | +20% | Q2 2026 |
| EPS | −$1.01 | −3.8% | Q2 2026 |
| ROE | −16% | n/a | Q2 2026 |
| ROA | −15% | n/a | Q2 2026 |
| Free cash flow | −$225M | +37% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Structure Therapeutics Inc. (GPCR) · Net incomeNet incomeStructure Therapeutics Inc. (GPCR)